Basic Information
| LncRNA/CircRNA Name | SNHG20 |
| Synonyms | NA |
| Region | GRCh38_17:77086716-77094990 |
| Ensemble | ENSG00000234912 |
| Refseq | NR_027058 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot |
| Sample | osteosarcoma tissues, cell lines (HOS, U-2 OS, Saos-2, MG-63, hFOB 1.19) |
| Expression Pattern | up-regulated |
| Function Description | Our results indicated SNHG20 was overexpressed in osteosarcoma tissues and cell lines. SNHG20 expression was negatively associated with overall survival. SNHG20 promoted osteosarcoma cell migration and invasion through modulating epithelial-mesenchymal transition-associated genes. |
| Pubmed ID | 30120876 |
| Year | 2018 |
| Title | LncRNA SNHG20 is associated with clinical progression and enhances cell migration and invasion in osteosarcoma. |
External Links
| Links for SNHG20 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |